Received Mar 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Vomiting; Weakness; Dizziness; Chills; This non-serious case was reported by a consumer via call center representative and described the occurrence of vomiting in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on an unknown date). On 02-MAR-2026, the patient received the 2nd dose of Shingrix. In MAR-2026, less than a week after receiving Shingrix, the patient experienced vomiting (Verbatim: Vomiting), weakness (Verbatim: Weakness), dizziness (Verbatim: Dizziness) and chills (Verbatim: Chills). The outcome of the vomiting, weakness, dizziness and chills were unknown. It was unknown if the reporter considered the vomiting, weakness, dizziness and chills to be related to Shingrix. It was unknown if the company considered the vomiting, weakness, dizziness and chills to be related to Shingrix. Additional Information: GSK Receipt Date: 03-MAR-2026 The batch number was not provided and request for this information has been made.